XCUR (Exicure, Inc. Common Stock) Stock Analysis - News
Exicure, Inc. Common Stock (XCUR) is a publicly traded Healthcare sector company. As of May 21, 2026, XCUR trades at $2.76 with a market cap of $19.50M and a P/E ratio of -3.70. XCUR moved +2.08% today. Year to date, XCUR is -46.89%; over the trailing twelve months it is -70.69%. Its 52-week range spans $2.15 to $36.00. Rallies surfaces XCUR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in XCUR news today?
Exicure and Adbiotech to Co-Develop Burixafor for Sickle Cell, AML and Solid Tumors: Exicure has signed a co-development deal with Adbiotech to test its CXCR4 antagonist Burixafor in combination therapies for sickle cell disease, acute myeloid leukemia and solid tumors. Adbiotech will run in vivo and preclinical studies while Exicure supplies Burixafor and leads clinical and regulatory strategy toward potential IND-enabling studies.
Exicure HiTron Inc. sold 258.37K (~$1.16M) on Jan 21, 2026.
Exicure HiTron Inc. sold 734.75K (~$3.31M) on Jan 16, 2026.
Exicure HiTron Inc. sold 741.27K (~$3.34M) on Jan 7, 2026.
XCUR Analyst Consensus
XCUR analyst coverage data. Average price target: $0.00.
Common questions about XCUR
What changed in XCUR news today?
Exicure and Adbiotech to Co-Develop Burixafor for Sickle Cell, AML and Solid Tumors: Exicure has signed a co-development deal with Adbiotech to test its CXCR4 antagonist Burixafor in combination therapies for sickle cell disease, acute myeloid leukemia and solid tumors. Adbiotech will run in vivo and preclinical studies while Exicure supplies Burixafor and leads clinical and regulatory strategy toward potential IND-enabling studies.
Does Rallies summarize XCUR news?
Yes. Rallies summarizes XCUR news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is XCUR research on Rallies investment advice?
No. Rallies provides research, data, and educational context for XCUR. It does not provide personalized investment advice.
